Dysgeusia and xerostomia of diverse severity have also been documented, especially under anti-PD-1/PD-L1 treatment, and they are attributed to CD4/CD8-T-cell toxicity against the salivary glands [5,79]. Here, CD4 is linked to xerostomia.